EMA/418666/2021

European Medicines Agency decision

P/0330/2021

of 11 August 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for cefepime / zidebactam (EMEA-002892-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0330/2021

of 11 August 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for cefepime / zidebactam (EMEA-002892-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Wockhardt Bio AG on 13 September 2020 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 25 June 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for cefepime / zidebactam, powder for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for cefepime / zidebactam, powder for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Wockhardt Bio AG, Grafenauweg 6, 6300 - ZUG, Switzerland.

EMA/PDCO/198123/2021
Amsterdam, 25 June 2021

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-002892-PIP01-20

Scope of the application

Active substance(s):

Cefepime / zidebactam

Condition(s):

Treatment of complicated urinary tract infections

Pharmaceutical form(s):

Powder for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Wockhardt Bio AG

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Wockhardt Bio AG submitted for agreement to the European Medicines Agency on 13 September 2020 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 13 October 2020.

Supplementary information was provided by the applicant on 13 March 2021.

The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation.
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Icelandic Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Treatment of complicated urinary tract infections

2.1.1. Indication(s) targeted by the PIP

Treatment of complicated urinary tract infections including pyelonephritis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	2	**Study 1** Pharmaceutical compatibility and stability analyses of the reconstituted solution for infusion at drug concentrations applicable to paediatric patients from a gestational age of 32 weeks with regards to excipients, solvent, minimum and maximum volume and duration of administration, local tolerability **Study 2** Development of an age-appropriate formulation for the paediatric population in case the simulations and planned probability of target attainment analyses and results of the planned clinical paediatric studies, demonstrate that the current cefepime / zidebactam ratio (2:1) is not appropriate in children
Non-clinical studies	1	**Study 3** Definitive juvenile beagle toxicity study to evaluate the toxicity, including delayed toxicity and recovery, and toxicokinetics of zidebactam

Clinical studies	2	**Study 4** Open-label, multicentre study to evaluate the pharmacokinetics, tolerability and safety of cefepime / zidebactam single dose in paediatric patients from 2 months to less than 18 years of age treated with parenteral antibiotics for a confirmed or suspected acute serious Gram-negative infection (W-5222-106) **Study 5** Open-label, multicentre study to evaluate the pharmacokinetics, tolerability and safety of cefepime / zidebactam single dose (part I) and of cefepime / zidebactam multiple doses (part II) in paediatric patients from birth to less than 2 months of age with late onset sepsis, complicated urinary tract infection or other confirmed serious acute Gram-negative infection (W-5222-107)
Extrapolation, modelling and simulation studies	2	**Study 6** Modelling and simulation study to define the doses and dose regimens of cefepime / zidebactam in the paediatric population from birth to less than 18 years of age with complicated urinary tract infections including pyelonephritis **Study 7** Extrapolation study to evaluate the use of cefepime / zidebactam in the paediatric population from birth to less than 18 years of age with complicated urinary tract infections including pyelonephritis
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes